Related Experiment Video
Updated: Jun 10, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with
Rika Kanezaki1, Tsutomu Toki, Kiminori Terui
1Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Abstract:
Twenty percent to 30% of transient abnormal myelopoiesis (TAM) observed in newborns with Down syndrome (DS) develop myeloid leukemia of DS (ML-DS). Most cases of TAM carry somatic GATA1 mutations resulting in the exclusive expression of a truncated protein (GATA1s). However, there are no reports on the expression levels of GATA1s in TAM blasts, and the risk factors for the progression to ML-DS are unidentified. To test whether the spectrum of transcripts derived from the mutant GATA1 genes affects the expression levels, we classified the mutations according to the types of transcripts, and investigated the modalities of expression by in vitro transfection experiments using GATA1 expression constructs harboring mutations. We show here that the mutations affected the amount of mutant protein. Based on our estimates of GATA1s protein expression, the mutations were classified into GATA1s high and low groups. Phenotypic analyses of 66 TAM patients with GATA1 mutations revealed that GATA1s low mutations were significantly associated with a risk of progression to ML-DS (P < .001) and lower white blood cell counts (P = .004). Our study indicates that quantitative differences in mutant protein levels have significant effects on the phenotype of TAM and warrants further investigation in a prospective study.
Insights
Lower levels of the mutant GATA1s protein in transient abnormal myelopoiesis (TAM) are linked to an increased risk of developing myeloid leukemia of Down syndrome (ML-DS). This finding highlights the importance of mutant protein levels in TAM progression.
Area of Science:
- Hematology
- Genetics
- Pediatric Oncology
Background:
- Transient abnormal myelopoiesis (TAM) affects newborns with Down syndrome (DS), with 20-30% progressing to myeloid leukemia of DS (ML-DS).
- Most TAM cases involve somatic GATA1 mutations leading to a truncated GATA1s protein, but its expression levels and role in ML-DS progression are unclear.
Purpose of the Study:
- To investigate whether different GATA1 mutations impact GATA1s expression levels.
- To determine if GATA1s expression levels are associated with the risk of progression from TAM to ML-DS.
Main Methods:
- Classified GATA1 mutations based on transcript types and assessed expression via in vitro transfection experiments.
- Quantified GATA1s protein levels to categorize mutations into high and low expression groups.
- Analyzed phenotypic data from 66 TAM patients with GATA1 mutations.
Main Results:
- GATA1 mutations significantly affected the amount of mutant GATA1s protein produced.
- GATA1s low mutations were strongly associated with an increased risk of progression to ML-DS (P < .001).
- Lower GATA1s expression also correlated with reduced white blood cell counts in TAM patients (P = .004).
Conclusions:
- Quantitative differences in mutant GATA1s protein levels significantly influence the phenotype of TAM.
- GATA1s low expression is a potential risk factor for ML-DS development, warranting further prospective studies.
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Incomplete Dominance
Abnormal Proliferation
Differentiation of Common Myeloid Progenitor Cells

